Geron to Present at Upcoming Investor Conferences in April
Get Alerts GERN Hot Sheet
Join SI Premium – FREE
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in fireside chats at following investor conferences:
-
22nd Annual Needham Virtual Healthcare Conference
Thursday, April 20 at 10:15 a.m. ET
-
Stifel 2023 Virtual Targeted Oncology Days
Tuesday, April 25 at 2:00 p.m. ET
A webcast of each fireside chat and corporate presentation will be available through the Investor Relations section of Geron’s website under Events. Following each scheduled conference event, the related webcast will be archived and available for replay for a period of 30 days.
About Geron
Geron is a late-stage biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies. Its investigational first-in-class telomerase inhibitor, imetelstat, harnesses Nobel Prize winning science in a treatment that may alter the underlying course of these diseases. To learn more, visit http://www.geron.com/or follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230412005663/en/
Aron Feingold
Investor and Media Relations
[email protected]
[email protected]
Source: Geron Corporation
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nidec Announces Financial Results for Fiscal Year Ended March 31, 2026
- Tenet Adds First U.S. Exclusive Commercial Lender to Business Hub and Welcomes New West Coast Business Development Manager
- PowerBank Corporation Receives Additional 180-day Compliance Period from Nasdaq to Regain Compliance with Minimum Bid Price Requirement
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Stifel, Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share